COH Center for Advanced Cellular/Immuno Therapies

描述（由申请人提供）： City of Hope长期以来一直认识到学术机构和私营部门在治疗研究中不断变化的角色，并开发了基础设施和专业知识来支持AP 4 RFA中设想的合作类型，并寻求通过NCI的公私合作伙伴关系中心计划扩大和完善其使命。COH于1998年成立了应用技术开发中心（CATD），以汇集从COH科学家，我们的学术同事和我们的生物制药合作伙伴的实验室中出现的新兴技术的真正“从实验室到床边”开发所需的基础设施。作为对CATD的补充，COH投入了大量的机构资源来发展国家认可的生物信息学和生物统计学小组，并作为指定的国家综合癌症中心，建立了组织良好、合作伙伴可访问的以研究为重点的临床试验基础设施。在AP4中心的框架内组织，这些以应用技术为重点的资源将为拟议的AP4中心研究人员提供与外部合作伙伴合作的能力，从早期临床前开发到临床试验过程中快速测试和改进新生物制剂。在COH的AP4中心将是我们正在进行的战略使命的延伸，以增加学术研究在新兴治疗技术的共同发展的贡献。因此，拟议的中心将专注于细胞和免疫治疗，因为我们的潜在中心合作伙伴表示的兴趣，因为希望之城在这一领域的长期和广泛的专业知识。当今一些最有前途的新治疗机会在于免疫疗法，包括抗体和细胞技术。COH与生物制药公司在这些领域的现有和正在发展的合作活动将作为招募成员加入中心合作伙伴关系的基础。

DESCRIPTION (provided by applicant): City of Hope has long recognized the changing roles of academic institutions and the private sector in therapeutics research and has developed infrastructure and expertise to support the types of collaborations envisioned in the AP4 RFA and seeks to expand and refine it's mission through the NCI's Public Private Partnership Center program. COH established its Center for Applied Technology Development (CATD) in 1998 to bring together the infrastructure needed for true 'bench-to-bedside" development of emerging technologies emerging from the laboratories of COH scientists, our academic colleagues, and our biopharmaceutical partners. Complementing the CATD, COH has invested significant institutional resources in developing nationally recognized bioinformatics and biostatistics groups and, as a designated National Comprehensive Cancer Center, a well-organized and partner-accessible research-focused clinical trials infrastructure. Organized within the framework of an AP4 Center, these applied technology-focused resources would offer the proposed AP4 Centers researchers, in collaboration with outside partners, the ability to rapidly test and refine new biologics from early pre-clinical development through the clinical trials process. An AP4 Center at the COH would be an extension of our ongoing strategic mission to increase the contribution of scholarly research in the co-development of emerging therapeutic technologies. Thus the proposed Center will focus on cellular and immuno-therapeutics because of the interests expressed by our prospective Center partners and because of City of Hopes long-standing and extensive expertise in this field. Some of today's most promising new therapeutic opportunities lie in immunotherapy, including antibody and cellular technologies. COH's existing and developing collaborative activities with biopharmaceutical companies in these areas will serve as the basis for recruiting Members to the Center Partnership.